ArticleEuropean journal of immunology2026
Viral Immunity in Immunoglobulin Products: Global Immunity Debt and Autoimmunity in the Postpandemic Era.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin (Ig) replacement therapy is commonly used to prevent infections in individuals with low IgG levels. These therapies are derived from pooled plasma donations from thousands of healthy individuals worldwide. This study examined 85 unique Ig batches produced between May 2017 and June 2023 to assess changes in antibody composition, particularly in response to the SARS-CoV-2 pandemic. Using high-throughput assays, IgG reactivity was measured against over 283,000 viral peptides from 527 virus species and nearly 12,000 human proteins. Antibodies against more than 200 virus species were detected, with 27-mainly respiratory and herpesviruses-present in over half the batches. SARS-CoV-2 antibodies emerged in products from July 2021 onward. During the pandemic, antibody levels against influenza, HSV-1, and enterovirus C declined, while those against RSV and Epstein-Barr virus increased. Autoantibodies targeting 55 human proteins were found in multiple batches, with TRIM21/Ro52 antibodies rising in parallel with SARS-CoV-2 antibodies. Principal component analysis showed that neither manufacturer nor geographic origin significantly explained overall antibody profiles, though some manufacturer-specific effects were noted in autoantibody content. These findings highlight pandemic-driven shifts in global antiviral immunity and autoantibody prevalence, with potential implications for immune health and autoimmune disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.